Median serum ficolin-1 concentration in AML patients before starting chemotherapy was almost fivefold lower than in healthy controls (260 ng/ml vs. 1,277 ng/ml; p < 0.000001, Mann–Whitney U-test), irrespective of complications recorded during hospital stay or FCN1 genotype (Fig. 1A, 2A, B). The gene discussed is FCN1; the disease is acute myeloid leukemia.